Volume 29, Number 3, 183-185, DOI: 10.1007/s10792-007-9186-y

Published in partnership with the

Logo

Society for Ophthalmo-Immuno Infectiology in Europe

Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri

Scott C. Jamerson, Guruswami Arunagiri, Brian D. Ellis and Monique J. Leys

View Related Documents

Abstract

Background In pseudotumor cerebri (PTC), elevated intracranial pressure (ICP) results in papilledema and, rarely, choroidal neovascularization (CNV). Pseudotumor cerebri-induced CNV often regresses following medical or surgical ICP reduction, but additional treatments, such as photocoagulation, photodynamic therapy, peri-ocular steroid injections and/or subretinal surgery, may be necessary. Anti-angiogenic intravitreal injections have been shown to cause regression of both CNV and optic nerve edema. Case report We describe a patient with PTC and CNV whose CNV regressed and vision normalized after a single intravitreal injection of bevacizumab (Avastin; Genentech, San Francisco, CA).

Keywords  Bevacizumab - Choroidal neovascularization - Pseudotumor cerebri

Fulltext Preview

Image of the first page of the fulltext document